Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,057 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for comparator Clear all
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

NCT00345384
View directory record Official record
Conditions
Post-operative Pain, Respiratory Depression
Interventions
Dexmedetomidine, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telomerase Activator and Retinal Amyloid

NCT02530255
View directory record Official record
Conditions
Alzheimer Disease
Interventions
cycloastragenol, placebo (for cycloastragenol)
Dietary Supplement
Lead sponsor
Chippewa Valley Eye Clinic
Other
Eligibility
50 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 4, 2026, 5:59 AM EDT
Not yet recruiting Not applicable Interventional

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

NCT06953635
View directory record Official record
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Combined Pharmacotherapies for Alcoholism

NCT00768508
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 4, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ascending Glycan Dietary Supplementation in Healthy Adults

NCT04466761
View directory record Official record
Conditions
Healthy Individuals
Interventions
Monosaccharide Powder, Placebo Comparator
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 4, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

ENA-001 for Opioid Induced Respiratory Depression

NCT06967259
View directory record Official record
Conditions
Respiratory Depression
Interventions
ENA-001, Placebo Comparator
Drug
Lead sponsor
Enalare Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Overland Park, Kansas • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2

NCT06068946
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735, Placebo
Biological
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use

NCT00479180
View directory record Official record
Conditions
Hemodialysis Access
Interventions
Vascugel, Placebo Comparator
Biological
Lead sponsor
Pervasis Therapeutics, Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166
View directory record Official record
Conditions
Early Stage Parkinson Disease
Interventions
Pardaprunox, pramipexole, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 4, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2Phase 3 Interventional

Cranberry Juice for Treatment of Urinary Tract Infections

NCT00093054
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cranberry juice, Placebo cranberry juice
Drug · Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

NCT07102459
View directory record Official record
Conditions
Acute Pain, Postoperative Pain Control
Interventions
Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator
Drug
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

NCT02477423
View directory record Official record
Conditions
Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions
Ampicillin, Gentamicins, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 6 Hours
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

NCT00215137
View directory record Official record
Conditions
OCD
Interventions
escitalopram, Placebo ( sugar pill)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Certolizumab pegol, Placebo
Biological · Drug
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Fiber Supplement on Gut Health

NCT07755735
View directory record Official record
Conditions
Gut Health, Bloating, Irregular Bowel Movements, Gastrointestinal Symptoms
Interventions
Active Supplement, Placebo Comparator
Dietary Supplement
Lead sponsor
Belli Welli Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 4, 2026, 5:59 AM EDT